BOSTON SCIENTIFIC CORPBSX

時価総額

$1433.3億

PER

低侵襲医療向け医療機器の最大手で45年超の歴史。心血管・末梢・泌尿器向けのデバイスと低侵襲治療ソリューションを展開。2024年9月に同業を約11.3億ドルで、11月に約34.1億ドルで買収。127カ国で展開。

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income (loss)	-1,065	441	-4,068	-121	-119	-239	347	104	1,671	4,700	-82	1,041	698	1,592	1,846
Loss (gain) on disposal of businesses and assets	-	778	15	38	12	-	-	-	-	8	-	78	-22	-	-
Depreciation and amortization	-	717	683	689	725	769	815	844	894	1,011	1,123	1,093	1,136	1,196	1,269
Deferred and prepaid income taxes	-	46	-166	-223	-397	-532	-305	245	-87	-4,301	-82	-124	-63	-1	-70
Stock-based compensation expense	150	128	108	105	103	107	116	127	140	157	170	194	220	233	266
Goodwill and other intangible asset impairment charges	-	21	142	53	195	19	11	4	35	105	533	370	132	58	386
Net loss (gain) on investments and notes receivable	-	27	37	-9	27	-9	-21	-92	155	-30	398	250	-1	-59	-79
Contingent consideration net expense (benefit)	-	-	-	-	-	-	29	-80	-21	-35	-100	-136	35	58	-5
InventoryStepUpAmortization	-	-	-	-	-	36	22	10	6	46	58	34	32	6	51
Other, net	-	-	-	-	-	-	-	-	-	-	-	-	-	73	74
Trade accounts receivable	-	-42	-37	101	-53	17	216	30	110	130	-335	279	220	238	351
Inventories	5	54	-66	7	81	-3	-40	107	83	290	65	346	321	660	228
Other assets	-132	60	68	-91	33	23	253	20	172	-45	200	134	209	-10	126
Accounts payable, accrued expenses and other liabilities	-1,148	-271	-131	-37	620	-20	553	195	-631	111	88	408	-255	118	243
Cash provided by (used for) operating activities	325	1,008	1,260	1,082	1,269	600	972	1,426	310	1,836	1,508	1,870	1,526	2,503	3,435
Purchases of property, plant and equipment and internal use software	272	304	226	245	259	247	376	319	316	461	376	554	588	711	790
Proceeds from sale of property, plant and equipment	5	16	16	53	-	-	29	-	14	7	12	14	12	4	3
Payments for acquisitions of businesses, net of cash acquired	199	370	366	274	486	1,734	408	560	1,448	4,382	3	2,258	1,542	1,811	4,640
Payments for investments and acquisitions of certain technologies	-	-	-	-	-	-	-	-	-	-	-	-279	24	89	280
Proceeds from Divestiture of Businesses	-	-	-	-	-	-	-	-	-	-	15	826	5	-	-
Proceeds from royalty rights	6	-5	-9	-5	-14	-61	-	-	-	-	-87	-82	-70	-30	-20
Proceeds from settlements of hedge contracts	-	-	-	-	-	-	-	-	-	-	-	-15	-56	-2	-
Cash provided by (used for) investing activities	-480	769	-579	-475	-745	-2,186	-887	-1,010	-1,921	-5,041	-411	-1,597	-2,011	-2,574	-5,687
Payment of contingent consideration previously established in purchase accounting	-	-	-	-	-	-	-	-	-	-	49	15	335	39	131
Payments for royalty rights	-	-	-	-	-	-	-	-	-	-	97	85	75	50	26
Payments for finance leases	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25
Payments on short-term borrowings	-	-	-	-	-	-	-	-	-	1,000	2,950	-	250	-	504
Proceeds from Short-Term Debt	-	-	-	-	-	-	-	-	999	700	2,245	-	-	-	24
Net increase (decrease) in commercial paper	-	-	-	-	-	-	-	1,183	21	-575	-714	-	-1	-4	187
Payments on long-term borrowings and debt extinguishment costs	-	-	-	-	-	-	-	-	-	-	1,260	-	3,184	-	-
Proceeds from Issuance of Senior Long-Term Debt	-	-	-	-	-	-	-	-	-	-	1,683	-	3,270	-	2,145
Cash dividends paid on preferred stock	-	-	-	-	-	-	-	-	-	-	28	55	55	28	-
Cash used to net share settle employee equity awards	-	-	-	-	-	-	62	65	56	65	59	50	53	56	87
Proceeds from Stock Plans	-	-	-	-	-	-	-	-	-	-	111	110	136	182	230
Cash provided by (used for) financing activities	-496	-1,721	-744	-596	-150	1,322	-206	110	1,432	2,973	293	-95	-548	5	1,814
Effect of foreign exchange rates on cash	-	-	-	-	-	-	-	-	-	-	-2	-6	-9	-4	-11
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	-	-	-	-	-	-	-	-	-	-	1,388	173	-1,042	-70	-450
Income Taxes Paid	-	138	97	67	74	80	94	-	-	-	207	302	662	512	656
Cash paid for interest	328	-	-	-	-	-	-	-	-	449	359	338	450	259	250
Fair value of contingent consideration recorded in purchase accounting	-	-	-	-	-	-	-	-	248	127	-	440	-	273	29